{
    "clinical_study": {
        "@rank": "119290", 
        "arm_group": {
            "arm_group_label": "Abatacept", 
            "arm_group_type": "Experimental", 
            "description": "Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy of Abatacept after intravenous\n      administration in Japanese children and adolescents with active juvenile idiopathic\n      arthritis who have a history of an inadequate response or intolerance to Methotrexate or\n      biologics"
        }, 
        "brief_title": "Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Juvenile Idiopathic Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Juvenile Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have a history of an inadequate therapeutic response or intolerance in\n             the opinion of the examining physician to at least one biologics or  Methotrexate\n             (MTX).\n\n          -  Diagnosis of Juvenile Idiopathic Arthritis (JIA) by International League of\n             Associations for Rheumatology (ILAR) criteria as oligoarticular, polyarticular\n             Rheumatoid Factor (RF+), polyarticular (RF-), or systemic with a\n             polyarticular-course.\n\n          -  Men and women, ages 4 to 17 years, inclusive at enrollment.\n\n          -  Subjects must have a history of at least 5 joints with active disease and must have\n             currently active articular disease as defined by:\n\n               1. \u22652 active joints (e.g. presence of swelling, or if no swelling is present,\n                  limitation of motion (LOM) accompanied by pain, tenderness, or both) at\n                  screening and at Week 0 (Day 1).\n\n               2. \u22652 joints with LOM at screening and at Week 0 (Day 1).\n\n        Exclusion Criteria:\n\n          -  Systemic onset JIA with any of the following manifestations within the last 6 months\n             prior to enrollment: intermittent fever due to JIA, rheumatoid rash,\n             hepatosplenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.\n\n          -  Presence of any other rheumatic disease or major chronic\n             infectious/inflammatory/immunologic disease (e.g. inflammatory bowel disease,\n             psoriatic arthritis, spondyloarthropathy, hypogammaglobulinemia, or systemic lupus\n             erythematosus, etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835470", 
            "org_study_id": "IM101-365"
        }, 
        "intervention": {
            "arm_group_label": "Abatacept", 
            "intervention_name": "Abatacept", 
            "intervention_type": "Drug", 
            "other_name": [
                "BMS-188667", 
                "ONO-4164"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Abatacept"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Site 0004"
                }, 
                "facility": {
                    "address": {
                        "city": "Oobu-shi", 
                        "country": "Japan", 
                        "state": "Aichi", 
                        "zip": "4748710"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0011"
                }, 
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan", 
                        "state": "Hokkaido", 
                        "zip": "0048618"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0005"
                }, 
                "facility": {
                    "address": {
                        "city": "Kobe-shi", 
                        "country": "Japan", 
                        "state": "Hyogo", 
                        "zip": "6540081"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0002"
                }, 
                "facility": {
                    "address": {
                        "city": "Kagoshima-shi", 
                        "country": "Japan", 
                        "state": "Kagoshima", 
                        "zip": "8900075"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0001"
                }, 
                "facility": {
                    "address": {
                        "city": "Yokohama-shi", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "2360004"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0003"
                }, 
                "facility": {
                    "address": {
                        "city": "Sendai-shi", 
                        "country": "Japan", 
                        "state": "Miyagi", 
                        "zip": "9893126"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0010"
                }, 
                "facility": {
                    "address": {
                        "city": "Niigata-shi", 
                        "country": "Japan", 
                        "state": "Niigata", 
                        "zip": "9518520"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0008"
                }, 
                "facility": {
                    "address": {
                        "city": "Takatsuki-shi", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "5698686"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0007"
                }, 
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "1138603"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0006"
                }, 
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "1620054"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Institutional Review Board", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ACR pediatric 30 response is defined as '\u226530% improvement' and '\u22653 of the 6 Juvenile Idiopathic Arthritis (JIA) core set'\nAnd \u226530% worsening in not more than 1 of the 6 JIA core set variables", 
            "measure": "American College of Rheumatology (ACR) Pediatric 30 response rate", 
            "safety_issue": "No", 
            "time_frame": "Week 16 (Day 113)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "ACR pediatric 50 and 70 response rates", 
                "safety_issue": "No", 
                "time_frame": "Week 16 (Day 113)"
            }, 
            {
                "measure": "Disability index of the Childhood Health Assessment Questionnaire (CHAQ)", 
                "safety_issue": "No", 
                "time_frame": "Week 16 (Day 113)"
            }, 
            {
                "measure": "Safety summarized by proportion of subjects with Adverse Events (AEs), deaths, Serious Adverse Events (SAEs), and AEs of special interest", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 16 (Day 113) - Short term (ST) period"
            }, 
            {
                "description": "Pharmacokinetics summary statistics (geometric mean and coefficient of variation) will be presented for Cmax", 
                "measure": "Maximum observed concentration (Cmax) of Abatacept", 
                "safety_issue": "No", 
                "time_frame": "9 time points up to Week 16 (Day 113) - ST period"
            }, 
            {
                "description": "Pharmacokinetics summary statistics (geometric mean and coefficient of variation) will be presented for Ctrough", 
                "measure": "Trough observed concentration (Ctrough) of Abatacept", 
                "safety_issue": "No", 
                "time_frame": "9 time points up to Week 16 (Day 113) - ST period"
            }, 
            {
                "description": "Assessment of positive response is determined based on an assay cutpoint value. For the electrochemiluminescence (ECL) assay, for all summaries and listings unless specified otherwise, a positive immunogenicity response for 'Cytotoxic T-lymphocyte antigen (CTLA4) and possibly Immunoglobulin (Ig)', 'Ig and/or Junction Region', respectively, is defined as:\nA missing baseline immunogenicity measurement and a positive analytical laboratory reported immunogenicity response post-baseline\nA negative baseline immunogenicity response and a positive analytical laboratory reported immunogenicity response post-baseline\nA positive baseline immunogenicity response and a positive analytical laboratory reported immunogenicity response post-baseline that has a titer value strictly greater than the baseline titer value", 
                "measure": "Immunogenicity positive rates", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 16 (Day 113) - ST period"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": {
                "agency": "Ono Pharmaceutical Co. Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}